April 26, 2024
Waiting for PCE, PE, CORE and UN of Michigan inflation-oriented reports
News: The FDA approved Pfizer’s (PFE +$0.23 or +0.91%) treatment for a genetic bleeding disorder, its first-ever gene therapy -- Beqvez, for adults with moderate to severe hemophilia B to win clearance in the U.S. PFE’s treatment will be available by prescription to eligible patients this quarter and has a hefty $3.5 million price tag before insurance and other rebates.
It's a daunting task to understand risk, seeing the unforeseen; on the basis of my own “rules”, I set-up my own “warning analysis” which isn’t machine oriented!
We crave explanations because they give us an illusion of control.
Never leave an investor uninformed!
April 12, 2024
Watch on Netflix: “Bad Surgeon, Love under the Knife” a back story involving Harvard Apparatus RN (HRGN) … < www.hregen.com > formerly Biostage and Dr. Paolo Macchiarini formerly a world famous for his revolutionary stem cell-infused windpipe transplants.
“There's just one problem: His patients kept dying.”
Also answers the question of WHY Biostage (BSTG) and its former Chairman, CEO Biostage and current board member David Green of re-named company paid $5 million dollars to the VICTIM’s family and they are trying to re-test the artificial esophageal windpipe yet again at two (2) locations!
Are the remaining investors ready for the upcoming private placement of share increasing outstanding shares!
April 26, 2024
News: bluebird bio (BLUE) is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) receiving a notice on 4/24/24 from because BLUE has not yet filed its 12/31/23 Annual Report on Form 10-K for the year with the SEC.
The Harvard Apparatus RT (OTCQB: HRGN) Chronicles: Ponzi Scheme, a Madoff look-a-life or just a China rip-off? <see the Bottom Line>
A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio’s defense or offence.
Never leave an investor uninformed! A trusted source of factual reporting!
The week in Review
April 12, 2024
Watch on Netflix: “Bad Surgeon, Love under the Knife” a back story involving Harvard Apparatus RN (HRGN) … < www.hregen.com > formerly Biostage and Dr. Paolo Macchiarini formerly a world famous for his revolutionary stem cell-infused windpipe transplants. “There's just one problem: His patients kept dying.” Also answers the question of WHY Biostage (BSTG) and its former Chairman, CEO Biostage and current board member David Green of re-named company paid $5 million dollars to the VICTIM’s family and they are trying to re-test the artificial esophageal windpipe yet again at two (2) locations! Are the remaining investors ready for the upcoming private placement of share increasing outstanding shares!
April 2, 2024
A scorecard of earnings releases of covered companies - The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status". 30 of 35 covered released to date
March 22, 2024
SGMO dived $0.1465 to $08238 or -15.098% And pre-funded warrants of 3,809,523 shares of common stock, together with accompanying warrants to purchase up to an aggregate of 28,571,428 shares of common stock priced at $0.83 Gross proceeds $24 M possible Barclays and Cantor are acting as placement agents for the offering
April 26, 2024
RegMed Investors (RMi) Closing Bell: I bowed the knee to thank the upside relief
April 26, 2024
RegMed Investors’ (RMi) pre-open: head and knee down
April 25, 2024
RegMed Investors (RMi) Closing Bell: hammered
April 25, 2024
RegMed Investors’ (RMi) pre-open: expectation versus reality
April 24, 2024
RegMed Investors (RMi) Closing Bell: I told you so
April 24, 2024
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!
April 23, 2024
RegMed Investors (RMi) Closing Bell: welcoming the upside trend
April 23, 2024
RegMed Investors’ (RMi) pre-open: finding our way